BioWorld

Feb. 12, 2002

View Archived Issues

United Therapeutics Receives Remodulin Approvable Letter

Following receipt of an approvable letter from the FDA, United Therapeutics Corp. said its orphan drug for pulmonary arterial hypertension should reach the market sometime in the next two months. (BioWorld Today) Read More

Deltagen Paying $23.5M For BMS Unit, Adding Discovery Capability

Read More

One Of 40 Myosin Proteins In Mammalian Body Led Mice To Key Hearing-Mechanism Clue

Read More

Inhibitex Closing $41M Round To Fund Product Development

Read More

CytRx, Global Genomics Merging In Deal Worth Up To $6.28M

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

U.S. Patent Disclosures

Read More